Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
We performed a win ratio (WR) analysis of REPRIEVE, a randomized trial of pitavastatin vs placebo for cardiovascular disease in people with human immunodeficiency virus to assess robustness to event severity. WR aligns with primary findings and provides insight into pitavastatin protections: persistent advantage on death, stroke, and myocardial infarction. Clinical Trials Registration . NCT02344290.
Authors
- Emma Smith (ORCID: https://orcid.org/0000-0001-8200-7908)
- Markella V. Zanni (ORCID: https://orcid.org/0000-0002-4711-3956)
- Heather J. Ribaudo (ORCID: https://orcid.org/0000-0002-0394-3990)
- Sarah M Chu
- James Troendle (ORCID: https://orcid.org/0000-0002-7903-1015)
- Amy Shirong Lu (ORCID: https://orcid.org/0000-0002-8230-9049)
- Pamela S. Douglas (ORCID: https://orcid.org/0000-0001-9876-4049)
- Steven Grinspoon (ORCID: https://orcid.org/0000-0002-6338-000X)
- Michael T. Lu (ORCID: https://orcid.org/0000-0003-4696-9610)
- Triin Umbleja (ORCID: https://orcid.org/0000-0001-7161-7743)
- Marissa R Diggs
- Sara McCallum (ORCID: https://orcid.org/0000-0002-0289-1295)
Institutions
- Harvard University (US)
- Duke University (US)
- Massachusetts General Hospital (US)
- Clinical Research Institute (US)
- Cancer Research And Biostatistics (US)
- National Heart, Lung, and Blood Institute (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1093/cid/ciaf477
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79